BACKGROUND. Although zidovudine is effective in patients with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. METHODS. This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less than or equal to 300 CD4 cells per cubic milliliter, or asymptomatic HIV infection with less than or equal to 200 CD4 cells per cubic milliliter. They were randomly assigned to receive 600 mg per day of zidovudine, 750 mg per day of didanosine, or 500 mg per day of didanosine. RESULTS. There were significantly fewer new AIDS-defining events and deaths among the 298 subjects assigned to 500 mg per day of didanosine than among the subjects who continued to receive zidovudine (relative risk, 1.39; 95 percent confidence interval, 1.06 to 1.82; P = 0.015). With 750 mg of didanosine, there was no clear benefit over zidovudine (relative risk, 1.10; 95 percent confidence interval, 0.86 to 1.42). The efficacy of didanosine was unrelated to the duration of previous zidovudine treatment. In the two didanosine groups, there were improvements in the number of CD4 cells (P less than 0.001 for both groups) and in p24 antigen levels (P = 0.03 in the 500-mg group; P = 0.005 in the 750-mg group), as compared with the zidovudine group. CONCLUSIONS. Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.
Source Information
San Francisco General Hospital, Calif. 94110.
This article has been cited by other articles:
Cooper, D. A.
(2002). Update on Didanosine. J Int Assoc Physicians AIDS Care (Chic Ill)
1: 15-25
[Abstract]
Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Katz, M. H.
(2000). Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996. Am J Epidemiol
152: 178-185
[Abstract][Full Text]
Patick, A. K., Potts, K. E.
(1998). Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev.
11: 614-627
[Abstract][Full Text]
Adams, J. M., Shelton, M. J., Hewitt, R. G., Grasela, T. H., DeRemer, M., Morse, G. D.
(1998). Relationship between Didanosine Exposure and Surrogate Marker Response in Human Immunodeficiency Virus-Infected Outpatients. Antimicrob. Agents Chemother.
42: 821-826
[Abstract][Full Text]
Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G.
(1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA
279: 450-454
[Abstract][Full Text]
Thomas, S. A., Segal, M. B.
(1997). . J. Pharmacol. Exp. Ther.
281: 1211-1218
[Abstract][Full Text]
Staszewski, S., Loveday, C., Picazo, J. J., Dellamonica, P., Skinhoj, P., Johnson, M. A., Danner, S. A., Harrigan, P. R., Hill, A. M., Verity, L., McDade, H.
(1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA
276: 111-117
[Abstract]
Katlama, C., Ingrand, D., Loveday, C., Clumeck, N., Mallolas, J., Staszewski, S., Johnson, M., Hill, A. M., Pearce, G., McDade, H.
(1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA
276: 118-125
[Abstract]
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., Volberding, P. A.
(1996). Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. JAMA
276: 146-154
[Abstract]
Moore, R. D., Keruly, J. C., Chaisson, R. E.
(1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med
156: 1073-1077
[Abstract]
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., Corey, L., The AIDS Clinical Trials Group,
(1996). Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. NEJM
334: 1011-1018
[Abstract][Full Text]
Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Rooney, J., Meng, T.-C., Fischl, M. A., Collier, A. C., Phair, J. P., Hirsch, M. S., Hardy, W. D., Balfour, H. H., Reichman, R. C., The AIDS Clinical Trials Group,
(1995). A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. NEJM
333: 401-407
[Abstract][Full Text]
(1995). Antiretroviral Drug Resistance: Clinical Significance and Implications for HIV Pathogenesis. AIDS Clin Care
1995: 1-1
[Full Text]
Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S.-h., Brown, M. J., Cross, A. P., Hirsch, M. S., Hardy, W. D., Mildvan, D., Blair, D. C., Powderly, W. G., Para, M. F., Fife, K. H., Steigbigel, R. T., Smaldone, L., AIDS Clinical Trials Group, , National Institute of Allergy and Infectious Disea, , National Institutes of Health, , Bristol-Myers Squibb, , Crumpacker, C. S., Cooley, T., Mitsuyaso, R. T., John, R., Sanders, C., Reitman, D., Hewitt, R., Reichman, R. C., Gelb, L. D., McGuire, M. L., Jones, M., Neidig, J. L., Zwickl, B., Hartman, P. B., Roarke, M. E., Burk, R. A., Fuhrer, J., Somogyi, K. A., Sepkowitz, K., Telzak, E. E., McAuliffe, V. J., Valentine, F. T., Vasquez, M., Merigan, T. C., Katzenstein, D., Fessell, J., Havlir, D. V., Richman, D. D., Spector, S. A., Kahn, J. O., Johnson, L., Coleman, R., Ho, M., McMahon, D., Pazin, G., Antoniskis, D., McNamara, B., Diamond, D., Collier, A. C., Paradise, M. A., Wald, A., DePaolis-Jones, A., Henry, K., Waskin, H. A., Hyslop, N. E. Jr, Mushatt, D. M., Zachary, J. A., Soeiro, R., Harris, C., Zingman, B., Giordano, M. F., Sledz, S., Murray, H. W., Carey, J. T., Davis, T. L., Bagby, B., Kessler, H. A., Murphy, R. I., Hirschtick, R. E., Cheeseman, S. H., Lai, K. K., Fairchild, P. G., Ehmann, W. C., Zurlo, J. J., Millard, R., Troiani, L., Heggen, A. A., van der Horst, C. M., McKinley, G. F., Grieco, M. H., Kolatch, B. R., Goldsmith, J. C., Gomperts, E. D., Woods, L. M., Grue, L., Mayjo, K., Becker, R. L., Jayaweera, D. T., Rolfe, L., Cole, J., Jermano, J.
(1995). Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine. Arch Intern Med
155: 961-974
[Abstract]
O'Connor, P. G., Selwyn, P. A., Schottenfeld, R. S.
(1994). Medical Care for Injection-Drug Users with Human Immunodeficiency Virus Infection. NEJM
331: 450-459
[Full Text]
Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H. Jr, Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., Soeiro, R., the AIDS Clinical Trials Group of the National Ins, , Pettinelli, C. B., Martinez, A. I., Liou, S.-H., Henry, K., Simpson, M., DePaolis-Jones, A., Hewitt, R. G., Blair, D. C., Packard, M. V., Fowler, C., Crumpacker, C. S., Allan, J. D., Fitch, H. F., Dybeck, K., Coleman, R., Jacobson, M., Phair, J. P., Murphy, R., Benson, C., Hardy, W. D., Chafey, S. A., Kruger, S., Reese, J., Dale, E., Harris, C., Steigbigel, N., Becker, R. L., Rexroad, V. E., Feinberg, J. E., Spector, S. A., Richman, D. D., Snyder, R., Merigan, T. C. Jr, Fessel, J., Katzenstein, D., Zachary, J. A., Mushatt, D. M., Hyslop, N. E. Jr, Collier, A. C., Corey, L., Coombs, R. W., Para, M. F., Fass, R. J., Whitacre, C., Sacks, H. S., Mildvan, D., Mendoza, H., Fife, K., Powderly, W. G., Gelb, L. D., Klebert, M., Leedom, J. M., Liggins, M., Quesada, N., Wong, B., Brinkdopke, J., Hoelle, M., Gocke, D. J., McAuliffe, V. J., Valentine, F. T., Dowling, J., Wallace, M., PaulJarrett, V., Cargill, V., McKinley, G. F., Grieco, M. H., Polsky, B., Brown, D. C., van der Horst, C., Fiscus, S., Ragan, D., Cheeseman, S. H., Fairchild, P. G., Lai, K. K., Ho, M., McMahon, D., Armstrong, J. A., Eyster, M. E., Ehmann, W. C., Irwin, D., Steigbigel, R. T., Fuhrer, J., Tenzler, R., Ponticello, L., Giordano, M. F., Murray, H. W.
(1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA
272: 437-442
[Abstract]
Moore, R. D., Stanton, D., Gopalan, R., Chaisson, R. E.
(1994). Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community. NEJM
330: 763-768
[Abstract][Full Text]
Abrams, D. I., Goldman, A. I., Launer, C., Korvick, J. A., Neaton, J. D., Crane, L. R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S., Cohn, D. L., Harris, A., Luskin-Hawk, R., Markowitz, N., Sampson, J. H., Thompson, M., Deyton, L., The Terry Beirn Community Programs for Clinical Re,
(1994). A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection. NEJM
330: 657-662
[Abstract][Full Text]
Saag, M. S.
(1994). What to Do When Zidovudine Fails. NEJM
330: 706-707
[Full Text]
Burack, J. H., Barrett, D. C., Stall, R. D., Chesney, M. A., Ekstrand, M. L., Coates, T. J.
(1993). Depressive Symptoms and CD4 Lymphocyte Decline Among HIV-Infected Men. JAMA
270: 2568-2573
[Abstract]
Fox, N. W., McArthur, C. P.
(1993). Acquired Immunodeficiency Syndrome-- A Review and Update: History, Characteristics of Human Immunodeficiency Virus Infection, Its Replication, Biologic Factors, and Pathogenicity. Arch Fam Med
2: 1068-1077
[Abstract]
Stoeckle, M. Y., Douglas, R. G. Jr
(1993). Infectious Diseases. JAMA
270: 223-224
[Abstract]
Landonio, G., Nosari, A., Spinelli, F., Pechere, M., Samii, K., Hirschel, B., Ballem, P., Belzberg, A., Devine, D.
(1993). HIV-Related Thrombocytopenia. NEJM
328: 1785-1786
[Full Text]
Hirsch, M. S., D'Aquila, R. T.
(1993). Therapy for Human Immunodeficiency Virus Infection. NEJM
328: 1686-1695
[Full Text]
Johnston, M., Hoth, D.
(1993). Present status and future prospects for HIV therapies. Science
260: 1286-1293
[Abstract]
Jewett, J. F., Hecht, F. M.
(1993). Preventive Health Care for Adults With HIV Infection. JAMA
269: 1144-1153
[Abstract]
